- Home
- USPH vs RLAY Comparison
USPH vs RLAY Comparison
Compare USPH & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USPH | RLAY |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | United States | United States |
| Employees | 5500 | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | USPH | RLAY |
|---|---|---|
| Price | $77.62 | $10.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $105.60 | $14.50 |
| AVG Volume (30 Days) | 185.8K | ★ 2.3M |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ 1.42 | N/A |
| Revenue | ★ $780,990,000.00 | $15,355,000.00 |
| Revenue This Year | $9.44 | N/A |
| Revenue Next Year | $6.43 | $396.00 |
| P/E Ratio | $56.23 | ★ N/A |
| Revenue Growth | 16.33 | ★ 53.44 |
| 52 Week Low | $62.77 | $1.78 |
| 52 Week High | $93.50 | $11.43 |
Technical Indicators
Market Signals| Indicator | USPH | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 33.74 | 64.10 |
| Support Level | $77.28 | $7.22 |
| Resistance Level | $83.08 | $11.43 |
| Average True Range (ATR) | 3.20 | 0.72 |
| MACD | -0.58 | 0.08 |
| Stochastic Oscillator | 34.40 | 69.42 |
Price Performance
Historical ComparisonAbout USPH U.S. Physical Therapy Inc.
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal payment sources for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).